| Patient | Charlotte Brontë |
|---|---|
| Date of birth | 1816-04-21 |
| Identifiers | MRN HR-NI025-SYN-TD; SSN (made up) 000-25-3804 |
| Document date | 2026-11-01 |
| Author | Eleanor Thwaite, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
First prenatal visit at 7 weeks with nausea and vomiting for a week and early weight loss: dating ultrasound, prenatal tests, and a plan for the nausea. Concerns: Nausea most of the day for a week and vomiting three or four times a day; she can no longer face meals and has lost about a kilogram; She is glad of the pregnancy but anxious about her age and about her own health, having lost her mother and her sisters young; She asks whether she could carry tuberculosis, since it was in her household. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe) | One tablet by mouth daily | Oral route | 1855-01-13 | active | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtime | Two tablets by mouth at bedtime | Oral route | 1855-01-13 to 1855-01-20 | completed | S |
| Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day) | One tablet in the morning, one mid-afternoon, and two at bedtime | Oral route | 1855-01-20 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before meals | One tablet by mouth three times a day, 30 minutes before meals | Oral route | 1855-01-20 to 1855-01-29 | completed | S |
| Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours | 1000 mL over 8 hours, guided by daily electrolytes | Intravenous route | 1855-01-29 to 1855-02-01 | completed | S |
| Thiamine 100 mg intravenously daily, the first dose before any dextrose | 100 mg intravenously once daily; first dose before any dextrose-containing fluid | Intravenous route | 1855-01-29 to 1855-02-01 | completed | S |
| Ondansetron 4 mg intravenously every 8 hours | 4 mg by slow intravenous injection every 8 hours | Intravenous route | 1855-01-29 to 1855-02-01 | completed | S |
| Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg) | 20 mg (0.2 mL) subcutaneously once daily while in hospital | Subcutaneous route | 1855-01-29 to 1855-02-01 | completed | S |
| Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once | 2 g intravenously over 1 hour, one dose | Intravenous route | 1855-01-29 to 1855-01-29 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours | One tablet on the tongue every 8 hours | Oral route | 1855-02-01 to 1855-02-24 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea | One tablet on the tongue up to every 8 hours if needed | Oral route | 1855-02-24 to 1855-03-24 | completed | S |
| Thiamine 100 mg oral tablet, one tablet by mouth three times a day | One tablet by mouth three times a day while intake is poor | Oral route | 1855-02-01 to 1855-02-24 | completed | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime | One tablet by mouth at bedtime until delivery | Oral route | 1855-02-24 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Transvaginal dating ultrasound: single live intrauterine pregnancy, crown-rump length 11 mm (7 weeks 1 day), cardiac activity present, no subchorionic hemorrhage, ovaries normal | 1855-01-13 to 1855-01-13 | completed | S |
| 12-lead electrocardiogram before intravenous ondansetron with hypokalemia: sinus tachycardia 106 per minute, QTc 438 ms, no other abnormality | 1855-01-29 to 1855-01-29 | completed | S |
| First-trimester ultrasound for nuchal translucency: single live fetus, crown-rump length 70 mm (13 weeks 1 day), nuchal translucency 1.5 mm, nasal bone present, no structural abnormality seen | 1855-02-24 to 1855-02-24 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1855-01-13 | Influenza vaccine, 1854-1855 season, given in pregnancy | completed | S |
| 1848-05-14 | Tdap vaccine | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| November 1854 | A bad lingering sore throat and cold after a long walk in heavy rain on the moors, which made her thin and weak | D (CLM-0009) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died in 1821 in her 39th year after a long and painful illness, possibly cancer | R (CLM-0003, CLM-0004) | |
| sister | Eldest sister: tuberculosis after illness at boarding school; died in 1825 aged 11 | 11 | D (CLM-0005) |
| sister | Second sister: tuberculosis after illness at boarding school; died in 1825 aged 10 | 10 | D (CLM-0005) |
| brother | Died in 1848 aged 31 of several conditions made worse by heavy drinking, with tuberculosis among them | 31 | D (CLM-0006) |
| sister | Tuberculosis; died in 1848 aged 30 | 30 | D (CLM-0007) |
| sister | Tuberculosis; died in 1849 aged 29 | 29 | D (CLM-0007) |
| Concern | Status | Evidence |
|---|---|---|
| Nausea most of the day for a week and vomiting three or four times a day; she can no longer face meals and has lost about a kilogram | active | S |
| She is glad of the pregnancy but anxious about her age and about her own health, having lost her mother and her sisters young | active | S |
| She asks whether she could carry tuberculosis, since it was in her household | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 11.6 on 1855-03-24; Leukocytes [#/volume] in Blood by Automated count 8.4 on 1855-01-13; Platelets [#/volume] in Blood by Automated count 248 on 1855-01-13; Sodium [Moles/volume] in Serum or Plasma 137 on 1855-02-10; Potassium [Moles/volume] in Serum or Plasma 4 on 1855-02-10; Chloride [Moles/volume] in Serum or Plasma 101 on 1855-02-10; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 1855-02-10; Urea nitrogen [Mass/volume] in Serum or Plasma 9 on 1855-02-10; Creatinine [Mass/volume] in Serum or Plasma 0.55 on 1855-02-10; Glucose [Mass/volume] in Serum or Plasma 82 on 1855-02-10; Ketones [Mass/volume] in Urine by Test strip 80 on 1855-01-29; Fetal Crown Rump length US 70 on 1855-02-24; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 5 on 1855-01-13; Magnesium [Mass/volume] in Serum or Plasma 1.9 on 1855-02-10; Phosphate [Mass/volume] in Serum or Plasma 3.4 on 1855-02-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 1855-02-10; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1855-02-10; Thyrotropin [Units/volume] in Serum or Plasma 0.92 on 1855-03-24; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 on 1855-03-24; Total score [EPDS] 5 on 1855-03-24; Fetal nuchal translucency measured by US 1.5 on 1855-02-24 [S]
Strengths and supports: Supports: her husband, a close friend from school days with whom she writes often, and the household's long-serving help [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 day | active | confirmed | O09.519 | S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019). |
| Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarum | resolved | confirmed | O21.9 | S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R. |
| Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14 | active | confirmed | O21.1 | S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis. |
| Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment needed | resolved | confirmed | O99.281 | S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1855-01-13 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 11-15.5 g/dL | Normal | S |
| 1855-01-13 | Leukocytes [#/volume] in Blood by Automated count | 8.4 | 10*3/uL | 4-13 10*3/uL | Normal | S |
| 1855-01-13 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1855-01-13 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1855-01-13 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1855-01-13 | Chloride [Moles/volume] in Serum or Plasma | 102 | mmol/L | 98-107 mmol/L | Normal | S |
| 1855-01-13 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 1855-01-13 | Urea nitrogen [Mass/volume] in Serum or Plasma | 8 | mg/dL | 6-20 mg/dL | Normal | S |
| 1855-01-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.52 | mg/dL | 0.4-0.9 mg/dL | Normal | S |
| 1855-01-13 | Glucose [Mass/volume] in Serum or Plasma | 76 | mg/dL | 70-99 mg/dL | Normal | S |
| 1855-01-13 | Ketones [Mass/volume] in Urine by Test strip | 15 | mg/dL | <=0 mg/dL | High | S |
| 1855-01-13 | Fetal Crown Rump length US | 11 | mm | Consistent with 7 weeks 1 day by the last menstrual period | Normal | S |
| 1855-01-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1855-01-20 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 1855-01-20 | Potassium [Moles/volume] in Serum or Plasma | 3.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1855-01-20 | Chloride [Moles/volume] in Serum or Plasma | 99 | mmol/L | 98-107 mmol/L | Normal | S |
| 1855-01-20 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 26 | mmol/L | 22-29 mmol/L | Normal | S |
| 1855-01-20 | Urea nitrogen [Mass/volume] in Serum or Plasma | 11 | mg/dL | 6-20 mg/dL | Normal | S |
| 1855-01-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.58 | mg/dL | 0.4-0.9 mg/dL | Normal | S |
| 1855-01-20 | Glucose [Mass/volume] in Serum or Plasma | 74 | mg/dL | 70-99 mg/dL | Normal | S |
| 1855-01-20 | Ketones [Mass/volume] in Urine by Test strip | 40 | mg/dL | <=0 mg/dL | High | S |
| 1855-01-29 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 11-15.5 g/dL | Normal | S |
| 1855-01-29 | Sodium [Moles/volume] in Serum or Plasma | 133 | mmol/L | 135-145 mmol/L | Low | S |
| 1855-01-29 | Potassium [Moles/volume] in Serum or Plasma | 3.1 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 1855-01-29 | Chloride [Moles/volume] in Serum or Plasma | 94 | mmol/L | 98-107 mmol/L | Low | S |
| 1855-01-29 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 31 | mmol/L | 22-29 mmol/L | High | S |
| 1855-01-29 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 6-20 mg/dL | High | S |
| 1855-01-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.71 | mg/dL | 0.4-0.9 mg/dL | Normal | S |
| 1855-01-29 | Glucose [Mass/volume] in Serum or Plasma | 68 | mg/dL | 70-99 mg/dL | Low | S |
| 1855-01-29 | Magnesium [Mass/volume] in Serum or Plasma | 1.6 | mg/dL | 1.7-2.2 mg/dL | Low | S |
| 1855-01-29 | Phosphate [Mass/volume] in Serum or Plasma | 2.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1855-01-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 66 | U/L | 7-35 U/L | High | S |
| 1855-01-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 10-35 U/L | High | S |
| 1855-01-29 | Thyrotropin [Units/volume] in Serum or Plasma | 0.03 | m[IU]/L | 0.1-2.5 mIU/L | Low | S |
| 1855-01-29 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 2.1 | ng/dL | 0.8-1.8 ng/dL | High | S |
| 1855-01-29 | Ketones [Mass/volume] in Urine by Test strip | 80 | mg/dL | <=0 mg/dL | High | S |
| 1855-02-10 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1855-02-10 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1855-02-10 | Chloride [Moles/volume] in Serum or Plasma | 101 | mmol/L | 98-107 mmol/L | Normal | S |
| 1855-02-10 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 1855-02-10 | Urea nitrogen [Mass/volume] in Serum or Plasma | 9 | mg/dL | 6-20 mg/dL | Normal | S |
| 1855-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.55 | mg/dL | 0.4-0.9 mg/dL | Normal | S |
| 1855-02-10 | Glucose [Mass/volume] in Serum or Plasma | 82 | mg/dL | 70-99 mg/dL | Normal | S |
| 1855-02-10 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 1855-02-10 | Phosphate [Mass/volume] in Serum or Plasma | 3.4 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1855-02-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 1855-02-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-35 U/L | Normal | S |
| 1855-02-10 | Total score [EPDS] | 9 | {score} | S | ||
| 1855-02-24 | Fetal Crown Rump length US | 70 | mm | Consistent with 13 weeks 1 day by the dating scan | Normal | S |
| 1855-02-24 | Fetal nuchal translucency measured by US | 1.5 | mm | <=3.5 mm | Normal | S |
| 1855-03-24 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 11-15.5 g/dL | Normal | S |
| 1855-03-24 | Thyrotropin [Units/volume] in Serum or Plasma | 0.92 | m[IU]/L | 0.2-3 mIU/L | Normal | S |
| 1855-03-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1855-03-24 | Total score [EPDS] | 5 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1855-01-13 | Body height | 152 | cm | S |
| 1855-01-13 | Body weight | 45.1 | kg | S |
| 1855-01-13 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 1855-01-13 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1855-01-13 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1855-01-13 | Heart rate | 84 | /min | S |
| 1855-01-13 | Respiratory rate | 14 | /min | S |
| 1855-01-13 | Body temperature | 36.7 | Cel | S |
| 1855-01-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1855-01-20 | Body height | 152 | cm | S |
| 1855-01-20 | Body weight | 44 | kg | S |
| 1855-01-20 | Body mass index (BMI) [Ratio] | 19 | kg/m2 | S |
| 1855-01-20 | Systolic blood pressure | 102 | mm[Hg] | S |
| 1855-01-20 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1855-01-20 | Heart rate | 92 | /min | S |
| 1855-01-20 | Respiratory rate | 14 | /min | S |
| 1855-01-20 | Body temperature | 36.8 | Cel | S |
| 1855-01-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1855-01-29 | Body height | 152 | cm | S |
| 1855-01-29 | Body weight | 42.6 | kg | S |
| 1855-01-29 | Body mass index (BMI) [Ratio] | 18.4 | kg/m2 | S |
| 1855-01-29 | Systolic blood pressure | 96 | mm[Hg] | S |
| 1855-01-29 | Diastolic blood pressure | 60 | mm[Hg] | S |
| 1855-01-29 | Heart rate | 108 | /min | S |
| 1855-01-29 | Respiratory rate | 16 | /min | S |
| 1855-01-29 | Body temperature | 36.9 | Cel | S |
| 1855-01-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1855-02-10 | Body height | 152 | cm | S |
| 1855-02-10 | Body weight | 43.6 | kg | S |
| 1855-02-10 | Body mass index (BMI) [Ratio] | 18.9 | kg/m2 | S |
| 1855-02-10 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1855-02-10 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1855-02-10 | Heart rate | 86 | /min | S |
| 1855-02-10 | Respiratory rate | 14 | /min | S |
| 1855-02-10 | Body temperature | 36.7 | Cel | S |
| 1855-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1855-02-24 | Body height | 152 | cm | S |
| 1855-02-24 | Body weight | 44.4 | kg | S |
| 1855-02-24 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 1855-02-24 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1855-02-24 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1855-02-24 | Heart rate | 82 | /min | S |
| 1855-02-24 | Respiratory rate | 14 | /min | S |
| 1855-02-24 | Body temperature | 36.6 | Cel | S |
| 1855-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1855-03-24 | Body height | 152 | cm | S |
| 1855-03-24 | Body weight | 46.2 | kg | S |
| 1855-03-24 | Body mass index (BMI) [Ratio] | 20 | kg/m2 | S |
| 1855-03-24 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1855-03-24 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1855-03-24 | Heart rate | 80 | /min | S |
| 1855-03-24 | Respiratory rate | 14 | /min | S |
| 1855-03-24 | Body temperature | 36.7 | Cel | S |
| 1855-03-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1855-01-13 | First prenatal visit at 7 weeks with nausea and vomiting for a week and early weight loss: dating ultrasound, prenatal tests, and a plan for the nausea | finished | S |
| 1855-01-20 | One-week review of nausea and vomiting, intake results, and maternal-fetal medicine consultation | finished | S |
| 1855-02-10 | Prenatal visit at 11 weeks: nausea and vomiting review and cell-free DNA screening | finished | S |
| 1855-02-24 | Prenatal visit at 13 weeks with the nuchal translucency scan and the low-dose aspirin decision | finished | S |
| 1855-03-24 | Prenatal visit at 17 weeks: nausea and vomiting review and thyroid recheck | finished | S |
| 1855-01-29 | Same-day sick visit for vomiting with dehydration at 9 weeks, with direct admission | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| First prenatal visit: dating ultrasound; blood count, blood group and antibody screen, rubella immunity, hepatitis B surface antigen, HIV, syphilis, and hepatitis C tests; urine culture; metabolic panel and urinalysis because of vomiting; influenza vaccine; folic acid 0.4 mg daily in place of the iron-containing prenatal vitamin while nausea lasts | completed | GL-USPSTF-AB, GL-CDC-PREGVAX | S |
| Nausea and vomiting, step by step: small frequent dry meals, fluids between meals, ginger if she wishes, and avoiding smells that trigger nausea; doxylamine-pyridoxine from today, raised to four tablets a day if needed; then a second drug (metoclopramide, promethazine, or ondansetron after counseling); PUQE-24 score, weight, pulse, blood pressure, and electrolytes at each visit; same-day review if she cannot keep fluids down for 24 hours or loses more than 5 percent of her pre-pregnancy weight | completed | GL-ACOG-NVP-2018, GL-RCOG-HG-2024 | S |
| Maternal-fetal medicine consultation for a first pregnancy at 38 with moderate nausea and vomiting and early weight loss: escalation thresholds, aneuploidy screening and diagnostic options, preeclampsia prevention, tuberculosis risk, and the plan for the rest of the pregnancy | completed | GL-ACOG-NVP-2018, GL-RCOG-HG-2024, GL-ACOG-ANEU-2020, GL-USPSTF-ASA-2021 | S |
| Aneuploidy screening offered to all, with diagnostic testing available: cell-free DNA from 10 weeks, a nuchal translucency scan at 11 to 14 weeks, or chorionic villus sampling or amniocentesis; a detailed anatomy scan at 18 to 22 weeks | completed | GL-ACOG-ANEU-2020 | S |
| Tuberculosis screening with an interferon-gamma release assay because of tuberculosis deaths in her household; a shielded chest radiograph and treatment decisions only if it is positive | completed | GL-USPSTF-LTBI-2023 | S |
| Mental health: PHQ-9 at intake and the EPDS in each trimester and after any admission, with support for the strain of severe vomiting and for anxiety rooted in family loss | completed | GL-ACOG-MH-2023, GL-USPSTF-PND-2019 | S |
| Preeclampsia prevention: low-dose aspirin 81 mg at bedtime from 12 to 16 weeks until delivery if she has one high-risk or more than one moderate-risk factor (she has two: first pregnancy and age 35 or older); blood pressure at every visit | completed | GL-USPSTF-ASA-2021 | S |
| Admission for hyperemesis gravidarum: 0.9% saline with potassium chloride guided by daily electrolytes; thiamine 100 mg intravenously before any dextrose, then orally; magnesium replacement; ondansetron after counseling and an electrocardiogram; stop metoclopramide; refeeding precautions with phosphate and magnesium checks as eating resumes; weight-adjusted enoxaparin while admitted; discharge when she keeps fluids and food down | completed | GL-ACOG-NVP-2018, GL-RCOG-HG-2024, GL-RCOG-VTE-2015 | S |
| Thyroid: suppressed TSH with a mildly raised free T4 during hyperemesis is gestational transient thyrotoxicosis; no antithyroid drug; repeat TSH and free T4 at 16 to 18 weeks, and test for TSH-receptor antibodies only if it persists or signs of Graves disease appear | completed | GL-ATA-PREG-2017, GL-ACOG-NVP-2018 | S |
| Monitoring while nausea and vomiting last: PUQE-24, weight, pulse, and blood pressure at every visit; electrolytes until stable on oral intake; liver tests if abnormal; mood each trimester; antiemetic side effects (drowsiness, restlessness or abnormal movements, constipation, palpitations) | completed | GL-ACOG-NVP-2018, GL-RCOG-HG-2024 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Nausea and vomiting mild (PUQE-24 score 6 or less) and weight back to her pre-pregnancy 46.0 kg by about 17 weeks | 1855-03-24 | completed | PUQE-24 score 4 and weight 46.2 kg at 17 weeks 1 day | S |
| Hydration and electrolytes normal within two weeks of any admission | 1855-02-10 | completed | Sodium, potassium, chloride, bicarbonate, magnesium, phosphate, and transaminases all normal nine days after discharge | S |
| An informed choice about aneuploidy screening and diagnostic testing by 13 weeks | 1855-02-24 | completed | Chose cell-free DNA screening (low risk) and the nuchal translucency scan (1.5 mm); declined diagnostic testing | S |
| Low-dose aspirin started between 12 and 16 weeks if indicated | 1855-02-24 | completed | Started at 13 weeks 1 day for two moderate risk factors | S |
| Tuberculosis screening completed and explained by the second visit | 1855-01-20 | completed | Interferon-gamma release assay negative; no latent infection; no chest radiograph needed | S |
| Mood screened in each trimester, with support offered | 1855-03-24 | completed | PHQ-9 5 at intake, EPDS 9 after the admission and 5 at 17 weeks; item 10 scored 0 each time | S |